A randomized phase 2 trial of first-line docetaxel, carboplatin, capecitabine (CTX) and epirubicin, oxaliplatin, capecitabine (EOX) in advanced esophagogastric adenocarcinoma

Figures & data

Figure 1. Consort diagram. CTX: carboplatin, docetaxel, and capecitabine; EOX: epirubicin; oxaliplatin, and capecitabine.

Table 1. Patient demographics and baseline characteristics (efficacy population).

Treatment (no. of patients)
	CTX (n = 49)			EOX (n = 49)			All (n = 98)
Characteristic	No. %			No. %			No. %
Sex
Male	37		75.5	42		85.7	79		80.6
Age, years
Median	66			63			64
Range	43-79			36-75			36-79
<70	30		61.2	39		79.6	69		70.4
≥70	19		38.8	10		20.4	29		29.6
ECOG Performance Status
0	20		40.8	26		53.1	46		46.9
1	29		59.2	23		46.9	52		53.1
Primary tumor site
Esophageal	13		26.5	16		32.7	29		29.6
Gastroesophageal junction	21		42.9	23		46.9	44		44.9
Gastric	15		30.6	10		20.4	25		25.5
Histology
Adenocarcinoma	46		93.9	49		100	95		97.0
MANEC	1		2.0	0		0	1		1.0
Carcinoma	2		4.1	0		0	2		2.0
Disease status
Locally advanced/recurrent	3		6.1	7		14.3	10		10.2
Metastatic	46		93.9	42		85.7	88		89.8
No. of organs involved
0 or 1	24		49.0	30		61.2	54		55.1
≥2	25		51.0	19		38.8	44		44.9
Prior therapy
Surgery	2		4.1	6		12.2	8		8.2
Neoadjuvant chemoradiotherapy	1		2.0	3		6.1	4		4.1
Perioperative chemotherapy	0		0	3		6.1	3		3.1

CTX: carboplatin, docetaxel, and capecitabine; EOX: epirubicin, oxaliplatin, and capecitabine; MANEC: mixed adenoneuroendocrine carcinoma

Figure 2. Progression-free survival outcomes. CI: confidence interval; CTX: carboplatin, docetaxel, and capecitabine; EOX: epirubicin, oxaliplatin, and capecitabine; PFS: progression-free survival.

Figure 3. Overall survival outcomes. CI: confidence interval. CTX: carboplatin, docetaxel, and capecitabine; EOX: epirubicin, oxaliplatin and capecitabine; OS: overall survival.

Table 2. Related hematologic and non-hematologic toxicities in >5% (NCIC CTC version 4.0).

Treatment (no. of patients)
	CTX (n = 51)		EOX (n = 51)
	Grade 3–4		Grade 3–4
Toxicity	No.	%	No.	%
Hematology
Neutropenia	42	82.4	27	52.9
Febrile neutropenia	16	31.4	7	13.7
Anemia	3	5.9	0	0
Non-hematologic
Diarrhea	4	7.8	0	0
Fatigue	3	5.9	0	0
Peripheral neuropathy	0	0	5	9.8
Nausea	0	0	3	5.9

CTX: carboplatin, docetaxel, and capecitabine; EOX: epirubicin, oxaliplatin and capecitabine.